Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25283986 | 1.00 | DNM1 (0.49) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL6574079 | 1.00 | DNM1 (0.49) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL19253788 | 0.98 | MEN1 (0.50) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6573992 | 0.98 | MEN1 (0.50) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL19253810 | 0.98 | MEN1 (0.50) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1255985 | 0.98 | MEN1 (0.50) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6572425 | 0.98 | MEN1 (0.50) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3688686 | 0.98 | MEN1 (0.50) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL645910 | 0.98 | MEN1 (0.50) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11153523 | 0.98 | MEN1 (0.50) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146765-B1 | A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2023-07-05 | — | — | EP | claimed |
| US-20230055665-A1 | DELIVERY CARRIER INTO CELL | ITO, KABUSIKIKAISYA (JP) | 2023-02-23 | — | — | US | claimed |
| JP-4838514-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1454638-B1 | Concentrated disinfecting composition based on quaternary ammonium compounds and their use for chemical-thermal care for instruments | BODE CHEMIE GMBH (DE) | 2010-12-22 | — | — | EP | claimed |
| EP-1471887-B1 | NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | ELAN PHARMA INT LTD (IE) | 2010-04-21 | — | — | EP | claimed |
| EP-1613276-A1 | LOW VISCOSITY LIQUID DOSAGE FORMS | Elan Pharma International Limited (IE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004050059-A1 | LOW VISCOSITY LIQUID DOSAGE FORMS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-06-17 | — | — | WO | claimed |
| EP-0034126-B1 | COSMETIC AND DERMATOLOGICAL COMPOSITIONS FOR SHAVING THE SKIN | Maggesi, Luigi (IT) | 1984-07-04 | — | — | EP | claimed |
| US-20240353412-A1 | A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2024-10-24 | — | — | US | disclosed |
| EP-4203904-A1 | COSMETIC COMPOSITIONS, KITS THEREOF, AND METHODS FOR MAKING AND USING THE SAME | L'OREAL (FR) | 2023-07-05 | — | — | EP | disclosed |
| EP-4146765-B1 | A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2023-07-05 | — | — | EP | disclosed |
| CN-101797245-B | Nanoparticulate fibrate formulations | 阿尔科姆斯制药爱尔兰有限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-101365449-B | Nanoparticulate benzothiophene formulations | ELAN PHARMA INT LTD | 2011-11-09 | — | — | CN | disclosed |
| EP-2263651-A2 | Low viscosity liquid dosage forms | Elan Pharma International Limited (IE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2006109183-A1 | INJECTABLE DEPOT FORMULATIONS AND METHODS FOR PROVIDING SUSTAINED RELEASE OF NANOPARTICLE COMPOSITIONS | PFIZER PRODUCTS INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006109177-A1 | INJECTABLE DEPOT FORMULATIONS AND METHODS FOR PROVIDING SUSTAINED RELEASE OF POORLY SOLUBLE DRUGS COMPRISING NANOPARTICLES | PFIZER PRODUCTS INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| CN-1668281-A | Nanoparticulate fibrate formulations | ELAN PHARMA INT LTD (IE) | 2005-09-14 | — | — | CN | disclosed |
| EP-1443912-A2 | COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS | Elan Pharma International Limited (IE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003030872-A2 | COMPOSITIONS HAVING A COMBINATION OF PARTICLES FOR IMMEDIATE RELEASE AND FOR CONTROLLED RELEASE | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2003-04-17 | — | — | WO | disclosed |
| CN-1225553-A | Antimicrobial composition, method for prepn. of same | KEMIRA CHEMICALS OY (FI) | 1999-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055665-A1 | DELIVERY CARRIER INTO CELL | CTSA, ATG4A, ATG7 | DNM1 2333/4885MEN1 4742/4885KMT2A 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.